Challenges of Diagnosing MSA vs. PD

A man performing Alzheimer's disease research

SYNTap Test Capabilities

This biomarker test can detect α-Synuclein with 87% sensitivity, 97% specificity, and 93.9% accuracy.

Specification Sheet

SYNTap Spec Sheet - Disease Lead

The diagnosis of MSA vs. PD represents a major challenge particularly in early stages of the disease due to overlapping symptoms.

There are indications that SYNTap Test can be useful as a diagnostic test for MSA vs. PD. We are working towards a clinical validation and actively looking to partner in this project.

“The α-synuclein-PMCA assay (SAA) can discriminate between samples of cerebrospinal fluid from patients diagnosed with Parkinson's disease and samples from patients with multiple system atrophy, with an overall sensitivity of 95.4%.”  (Ref.10)

Research Partnership

Amprion continues to research the role of the SYNTap Test in contributing to the diagnosis and as part of the treatment decision making for several neurodegenerative diseases.

We are actively looking for partners to accelerate diagnostics and treatment innovations. 

To explore potential collaboration, please email us:

Download the SYNTap Test Specification Sheet for details.


Amprion has some important news we need to share with you!

To improve patient access to the SYNTap® biomarker test (CSF), Amprion is reducing the self-pay price for tests with service dates on or after July 1, 2023.

Old self-pay price: $1500.00. New self-pay price: $995.00

Effective July 1, 2023, there is a New ABN (Advanced Beneficiary Notification) form for use when ordering the SYNTap® biomarker test (CSF) for patients on Medicare. Order Process

CPT/PLA – The SYNTap® test has been issued a dedicated PLA code to be used when billing: 0393U
We have applied to be a medicare provider and will soon be able to courtesy bill Medicare for your patients.